[ad_1]
The laboratory Pfizer and the german company BioNTech announced this Wednesday that the final analyzes of large-scale studies of their vaccine against covid-19 reveal a 95% effectiveness in preventing infections, even in older adults.
This is 5% above the figure that they reported 9 days ago, causing other laboratories, such as the Russian government or Moderna, to come out to announce their own results.
As they indicated, it did not present security problems either, so they will request an emergency authorization with the United States authorities within a few days, CNN found.
The company indicated that it counted 170 coronavirus infections in volunteers who participated in the tests, 162 of which were in those who received the placebo (saline injections, without the vaccine, to compare with the people who did receive it).
Meanwhile, another 8 were in participants who did receive the treatment.
“Efficacy was consistent across demographic groups by age, race and ethnicity. The efficacy observed in adults over 65 years of age was over 94% ”, indicated both firms.
In total, they noted, “there were 10 severe cases of covid-19 observed in the tests, with 9 of them occurring in the placebo group and another in the vaccinated group.”
For its part, the Data Monitoring Committee, the team that has been observing side effects, has not reported any serious safety concerns regarding the vaccine, they said. The only “severe” adverse effect, they said, was fatigue reported in 3.7% after the second dose.
“The results of the study mark an important step in this historic eight-month journey to present a vaccine capable of helping end this devastating pandemic,” said Albert Bourla, CEO of Pfizer, who will apply for marketing authorization “in about days ”to the US Food and Drug Administration (FDA).
[ad_2]
